Xinmin Yu

2.9k total citations · 1 hit paper
48 papers, 1.1k citations indexed

About

Xinmin Yu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Xinmin Yu has authored 48 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Xinmin Yu's work include Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Research Studies (18 papers) and Lung Cancer Diagnosis and Treatment (14 papers). Xinmin Yu is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Research Studies (18 papers) and Lung Cancer Diagnosis and Treatment (14 papers). Xinmin Yu collaborates with scholars based in China, Australia and New Zealand. Xinmin Yu's co-authors include Zhengbo Song, Yiping Zhang, Xun Shi, Jun Zhao, Ying Jin, Guangyuan Lou, Qiong He, Ming Chen, Guoping Cheng and Yanping Hu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Xinmin Yu

44 papers receiving 1.0k citations

Hit Papers

Tislelizumab Plus Chemoth... 2021 2026 2022 2024 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
    2021 246 citations Xinmin Yu, Jun Zhao et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xinmin Yu China 18 746 704 217 193 112 48 1.1k
Yasir Y. Elamin United States 16 595 0.8× 518 0.7× 164 0.8× 284 1.5× 127 1.1× 68 968
Sehhoon Park South Korea 18 543 0.7× 601 0.9× 229 1.1× 203 1.1× 95 0.8× 68 895
Xuezhi Hao China 21 733 1.0× 690 1.0× 216 1.0× 372 1.9× 64 0.6× 114 1.1k
Michele Prisciandaro Italy 15 566 0.8× 270 0.4× 146 0.7× 157 0.8× 119 1.1× 49 761
Hidenobu Ishii Japan 15 1.0k 1.4× 692 1.0× 217 1.0× 166 0.9× 74 0.7× 55 1.3k
Zhanhong Xie China 18 761 1.0× 519 0.7× 172 0.8× 227 1.2× 100 0.9× 60 1.1k
Paola Bordi Italy 17 800 1.1× 798 1.1× 353 1.6× 413 2.1× 54 0.5× 51 1.2k
Xingya Li China 18 613 0.8× 533 0.8× 245 1.1× 360 1.9× 103 0.9× 77 1.1k
Rocco Sacco Italy 11 658 0.9× 877 1.2× 255 1.2× 392 2.0× 103 0.9× 12 1.2k
Akito Hata Japan 25 1.1k 1.4× 1.4k 2.0× 325 1.5× 320 1.7× 111 1.0× 117 1.7k

Countries citing papers authored by Xinmin Yu

Since Specialization
Citations

This map shows the geographic impact of Xinmin Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinmin Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinmin Yu more than expected).

Fields of papers citing papers by Xinmin Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xinmin Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinmin Yu. The network helps show where Xinmin Yu may publish in the future.

Co-authorship network of co-authors of Xinmin Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Xinmin Yu. A scholar is included among the top collaborators of Xinmin Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xinmin Yu. Xinmin Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Shen, Lin, Caicun Zhou, Yinghua Ji, et al.. (2024). Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3012–3012. 9 indexed citations
3.
4.
Zhao, Jun, Xinmin Yu, Dingzhi Huang, et al.. (2023). SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 11(2). e006055–e006055. 15 indexed citations
5.
Pan, Yingying, Wenjing Xiao, Feng Ye, et al.. (2021). Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion. Annals of Translational Medicine. 9(12). 1014–1014. 5 indexed citations
6.
Chen, Lin, Xun Shi, Jun Zhao, et al.. (2020). Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer. Frontiers in Oncology. 10. 480–480. 20 indexed citations
7.
He, Qiong, Xian Lun Zhu, Xun Shi, et al.. (2020). cfDNA changes for monitoring of targeted therapy in a primary EGFR mutation lung adenocarcinoma. Translational Lung Cancer Research. 9(3). 807–810.
8.
Li, Hui, et al.. (2019). Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study. Cancer Chemotherapy and Pharmacology. 83(6). 1083–1090. 13 indexed citations
9.
Yu, Xinmin, et al.. (2018). Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and KRAS mutation. Journal of Cancer. 9(16). 2930–2937. 15 indexed citations
10.
Jin, Ying, Yamei Chen, Xinmin Yu, & Xun Shi. (2018). A real‑world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase‑positive non‑small‑cell lung cancer. Oncology Letters. 15(6). 8703–8710. 11 indexed citations
11.
Jin, Ying, Xun Shi, Jun Zhao, et al.. (2018). Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas. Lung Cancer. 124. 110–116. 48 indexed citations
12.
Song, Zhengbo, Xinmin Yu, Zhiyong Shi, Jun Zhao, & Yiping Zhang. (2016). HER2 mutations in Chinese patients with non-small cell lung cancer. Oncotarget. 7(47). 78152–78158. 23 indexed citations
13.
Song, Zhengbo, Xinmin Yu, Guoping Cheng, & Yiping Zhang. (2016). Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. Journal of Translational Medicine. 14(1). 188–188. 63 indexed citations
14.
Jin, Ying, Ming Chen, & Xinmin Yu. (2016). Comparison of the 7th and proposed 8th editions of the AJCC/UICC TNM staging system for non-small cell lung cancer undergoing radical surgery. Scientific Reports. 6(1). 33587–33587. 19 indexed citations
15.
Lou, Guangyuan, Xinmin Yu, & Zhengbo Song. (2016). Molecular Profiling and Survival of Completely Resected Primary Pulmonary Neuroendocrine Carcinoma. Clinical Lung Cancer. 18(3). e197–e201. 28 indexed citations
16.
Song, Zhengbo, Xinmin Yu, & Yiping Zhang. (2016). Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma. Lung Cancer. 99. 166–171. 46 indexed citations
17.
Jin, Ying, Ming Chen, & Xinmin Yu. (2016). Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer. Scientific Reports. 6(1). 31636–31636. 11 indexed citations
18.
Sun, Yan, Xinmin Yu, & Jinshi Liu. (2015). Treatment and prognosis of Masaoka stage 3 thymic carcinoma: a retrospective study of 32 cases. OncoTargets and Therapy. 8. 699–699. 2 indexed citations
19.
Zhao, Jun, et al.. (2015). Prognostic value of programed death ligand 1 in patients with solid tumors: A meta-analysis. Journal of Cancer Research and Therapeutics. 11(Suppl 1). S38–S43. 13 indexed citations
20.
Song, Zhengbo, et al.. (2013). Docetaxel‐based chemotherapy as second‐line regimen for advanced thymic carcinoma. Thoracic Cancer. 5(2). 169–173. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yasir Y. Elamin Breakdown of academic impact, for papers by Sehhoon Park Breakdown of academic impact, for papers by Xuezhi Hao Breakdown of academic impact, for papers by Michele Prisciandaro Breakdown of academic impact, for papers by Hidenobu Ishii Breakdown of academic impact, for papers by Zhanhong Xie Breakdown of academic impact, for papers by Paola Bordi Breakdown of academic impact, for papers by Xingya Li Breakdown of academic impact, for papers by Rocco Sacco Breakdown of academic impact, for papers by Akito Hata
Rankless by CCL
2026